Moderna Inc. and Merck & Co., Inc. said Wednesday that their personalized mRNA cancer vaccine met its primary and secondary endpoints in a Phase 3 trial [1, 2, 3].
The results mark a potential shift in oncology treatment by demonstrating that mRNA technology can be tailored to individual patients to prevent cancer recurrence. This development suggests a viable path for personalized immunotherapy beyond the company's well-known COVID-19 vaccines.
The trial involved 1,137 patients [1] who had undergone surgery to remove high-risk melanoma. The experimental treatment combined Moderna's personalized mRNA vaccine with Merck's immunotherapy drug, Keytruda. The companies said the combination therapy demonstrated a reduction in the risk of cancer recurrence, and metastasis [1, 2].
Investor reaction to the data was immediate and significant. Moderna shares rose 85% in pre-market trading following the announcement [4]. Other reports indicated the stock price more than doubled, representing an increase of over 100% [2].
Personalized mRNA vaccines work by analyzing the genetic mutations of a patient's specific tumor to create a custom treatment. This approach aims to train the immune system to recognize and attack remaining cancer cells that could lead to a relapse. The Phase 3 trial was conducted across global sites to verify the efficacy of this method in a large patient population [1].
While the companies have highlighted the success of the trial, the treatment must still undergo regulatory review before it becomes available to the general public. The partnership between Moderna and Merck represents a strategic effort to merge mRNA delivery systems with established checkpoint inhibitors like Keytruda to enhance the body's natural immune response against skin cancer [3].
“The trial involved 1,137 patients who had undergone surgery to remove high-risk melanoma.”
The success of this Phase 3 trial validates the application of mRNA technology in oncology, moving it from a theoretical possibility to a clinically proven method for reducing melanoma recurrence. For the biotech industry, this result suggests that the infrastructure built during the pandemic can be pivoted toward chronic and life-threatening diseases. If approved, the personalized nature of the vaccine would require a complex manufacturing pipeline for every individual patient, potentially redefining the logistics of cancer care.
